ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
出版年份 2022 全文链接
标题
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-11-10
DOI
10.3389/fimmu.2022.1040669
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvante Instillationstherapie des nicht muskelinvasiven Harnblasenkarzinoms – neue Optionen abseits von BCG und Mitomycin
- (2022) Georgios Gakis AKTUELLE UROLOGIE
- From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
- (2022) Susanne Deininger et al. Cancers
- N-803: a double-edged sword in haplo-NK therapy
- (2022) Daniela Pende et al. BLOOD
- Phosphate moiety in FDA‐approved pharmaceutical salts and prodrugs
- (2022) Ameya Fulmali et al. DRUG DEVELOPMENT RESEARCH
- Emerging treatment landscape of non-muscle invasive bladder cancer
- (2022) Carmine Valenza et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer
- (2022) Niyati Lobo et al. Expert Review of Anticancer Therapy
- Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
- (2022) Mark P. Rubinstein et al. JOURNAL OF IMMUNOLOGY
- Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
- (2022) Karim Chamie et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
- (2021) Fahad Quhal et al. WORLD JOURNAL OF UROLOGY
- Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
- (2021) Karim Chamie et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.
- (2021) Arjun Vasant Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer
- (2021) Vignesh T. Packiam et al. CURRENT OPINION IN UROLOGY
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
- (2021) Marko Babjuk et al. EUROPEAN UROLOGY
- Preclinical Models for Bladder Cancer Research
- (2021) Shaoming Zhu et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
- (2021) Arjun V Balar et al. LANCET ONCOLOGY
- Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer
- (2021) Michael Ahdoot et al. Expert Review of Clinical Pharmacology
- The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer
- (2021) Molly Beinfeld et al. Journal of Managed Care & Specialty Pharmacy
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- PD03-02 PHASE 3 RESULTS OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
- (2020) Neal Shore* et al. JOURNAL OF UROLOGY
- Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions
- (2020) John L. Pfail et al. WORLD JOURNAL OF UROLOGY
- Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
- (2019) Hideki Furuya et al. Journal of Translational Medicine
- Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer
- (2019) Jeffrey Huang et al. JOURNAL OF IMMUNOTHERAPY
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
- (2018) Bai Liu et al. CYTOKINE
- Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
- (2018) Italia Grenga et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Current Clinical Trials in Non-muscle Invasive Bladder Cancer
- (2018) Timo K. Nykopp et al. Current Urology Reports
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- MP15-12 PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAÏVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC).
- (2017) Charles J. Rosser et al. JOURNAL OF UROLOGY
- Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
- (2017) Caroline Jochems et al. Oncotarget
- Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer
- (2016) Ario Takeuchi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy
- (2016) Wei Xia Ang et al. Scientific Reports
- Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
- (2015) P. R. Rhode et al. Cancer Immunology Research
- p21WAF1 mediates the IL-15-induced migration and invasion of human bladder cancer 5637 cells via the ERK1/2/NF-κB/MMP-9 pathway
- (2014) Sung Lyea Park et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
- (2014) Evan Gomes-Giacoia et al. PLoS One
- Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
- (2012) Mike D. Shelley et al. BJU INTERNATIONAL
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
- (2011) T. A. Waldmann et al. BLOOD
- Intravesical Interleukin-15 Gene Therapy in an Orthotopic Bladder Cancer Model
- (2011) Kazuhiro Matsumoto et al. HUMAN GENE THERAPY
- Safety and immunologic effects of IL-15 administration in nonhuman primates
- (2009) C. Berger et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search